A detailed history of Capstone Investment Advisors, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Capstone Investment Advisors, LLC holds 18,358 shares of BCRX stock, worth $129,974. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,358
Holding current value
$129,974
% of portfolio
0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$7.55 - $9.06 $138,602 - $166,323
18,358 New
18,358 $139,000
Q2 2024

Aug 14, 2024

BUY
$4.13 - $6.79 $110,444 - $181,578
26,742 New
26,742 $165,000
Q4 2023

Feb 12, 2024

BUY
$4.98 - $6.77 $92,877 - $126,260
18,650 New
18,650 $111,000
Q2 2023

Aug 10, 2023

BUY
$6.96 - $8.81 $119,461 - $151,214
17,164 New
17,164 $120,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.32B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Capstone Investment Advisors, LLC Portfolio

Follow Capstone Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capstone Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capstone Investment Advisors, LLC with notifications on news.